Pfizer ending discovery, early neuroscience program

Pfizer Inc. (NYSE:PFE) said Friday it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the coming months" from its sites in Cambridge, Mass., Andover, Mass. and Groton, Conn.

On the chopping block are preclinical and Phase I/II programs primarily focused on Alzheimer's and Parkinson's disease. As of Oct. 31, Pfizer's pipeline listed eight neuroscience candidates in Phase I/II development. Spokesperson Steve Danehy told BioCentury the company is evaluating all ongoing discovery and early neuroscience development programs and will continue ongoing clinical trials as planned to completion. ...